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Evidence based medicine (EBM) clinical practice guide-
lines are rapidly evolving into very important tools for
improving patient care quality, improving patient clinical
outcomes, smoothing out unexplained variation in care
between providers, institutions, and geographic regions, as
well as reducing cost of health care delivery. This special
issue of the Journal of Neuro-Oncology presents the results
of the ﬁrst effort by the American Association of Neuro-
logical Surgeons (AANS), the Congress of Neurological
Surgeons (CNS) and the Joint Tumor Section (AANS/
CNS) to contract with an Agency for Healthcare Research
and Quality (AHRQ)—funded Evidence-based Practice
Center (EPC) to produce multidisciplinary evidence-linked
clinical practice guidelines for the treatment of a condition
that neurosurgery shares in common with many other
medical specialties. This collaboration resulted in the
methodologically highest quality EBM guidelines for the
treatment of patients with metastatic brain yet produced,
completed within 12 months of initiation, and published
within 16 months of initiation.
Why guidelines?
Given the seemingly exponential increase in the annual
volume of peer review literature, coupled with the signif-
icant time pressure associated with clinical practice, it is
becoming increasingly unlikely that any one practitioner
can keep current regarding all published evidence related to
their specialty, no matter how much they sub-specialize.
EBM clinical practice guidelines can help by providing a
starting point where a systematic evidence review up to one
point in time leads to practice recommendations supported
by best-evidence-to-date formulated by a multidisciplinary
panel of relevant specialty experts.
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oped statements to assist practitioner and patient decisions
about appropriate health care for speciﬁc individual cir-
cumstances [1]. Advantages of following guidelines rather
than expert opinion or individual randomized clinical trial
(RCT) results include: that professional expertise is taken
into account in aggregate, in a more systematic manner,
that more ‘‘experts’’ are involved (diluting outlier opin-
ions), that expert opinions are of the collected evidence
rather than their own personal experience, and that the
questions addressed in guidelines are more likely to be
relevant and ‘‘generalizable’’ to routine practice situations
than most inclusion/exclusion criteria of RCT’s.
Organized neurosurgery (AANS and CNS) has been
involved in EBM clinical practice guideline since 1993.
We have the longest experience with the severe head injury
guidelines produced originally produced in 1996 in a col-
laboration between the AANS and the Brain Trauma
Foundation (BTF) [2], with later revisions also involving
the CNS. Over the last 13 years these EBM clinical prac-
tice guidelines have been adopted by the American College
of Surgeons in their trauma center certiﬁcation program as
well as by the World Health Organization. They have now
clearly been shown to improve patient clinical outcomes as
well as reduce healthcare delivery costs [3, 4]. Acceptance
and implementation of EBM clinical guidelines has the
potential to smooth out unexplained variation in care
between providers, institutions, and geographic regions
without unjustiﬁed intrusion on practitioner autonomy or
clinical judgment. They may also become one of the best
sources for deriving disease- or procedure-speciﬁc process
quality measures with a better evidence base that consensus
process measures.
Guidelines differ in quality and importance
Guidelines construction involves two steps. First, a system-
atic means of identifying evidence and ranking the relative
strengths, or quality of each study as evidence. Second,
achieving panel agreement on strength of recommendation
linked to the analysis of the strength of evidence for each
intervention in question. Both steps are critically important
and have their own drawbacks and limitations. The ultimate
validityandusefulnessofanyguidelineiscriticallyrelatedto
three key factors: (1) the composition of the guideline panel
and its process, (2) the identiﬁcation and synthesis of the
evidence, and (3) the method of guideline construction
applied. Panel composition is crucial, both for ultimate
acceptance of the guidelines by practicing physicians, and
for its critical inﬂuence on the recommendation step of
guideline construction [5]. Panelist’s recommendations can
differ even when analyzing the same data [6–9].
In general, there are three different levels quality for
guidelines construction methodology; informal consensus
guidelines, formal consensus guidelines, and evidence-
linked construction [10]. The ﬁrst is most commonly found
in guidelines produced by patient support or advocacy
groups. They are often treatment algorithms produced
without a systematic evidence review and grading, and the
recommendations are usually not graded by strength. An
example for metastatic brain tumors is the International
RadioSurgery Association (IRSA), Stereotactic radiosur-
gery for patients with metastatic brain tumors guideline
[11]. The second can be evidence-based, in the sense that a
literature review is performed, but the evidence may, or
may not be graded in evidence tables, and the strength of
resultant recommendation are not limited by the strength of
supporting evidence. The evidence tables utilized in con-
struction are often not presented to allow for independent
veriﬁcation of evidence and recommendation strength
linkage. Examples of metastatic brain tumor guidelines
produced with this methodology include the four American
College of Radiology ACR Appropriateness Criteria

guidelines for metastatic brain tumors [12], and the two
National Cancer Institute (NCI), National Comprehensive
Cancer Network (NCCN) Clinical Practice Guidelines in
Oncology
TM
for metastatic brain tumors [13].
Evidence-linked methodology is the highest quality
construction methodology possible. They represent the
only guidelines with independent evidentiary status for
EBM decision making [1]. With this methodology, the
evidence tables are included for independent veriﬁcation of
adequacy of literature review and correctness of evidence
grading. Recommendations are graded by strength, but
strength of recommendation cannot exceed strength of
evidence supporting that recommendation regardless of
expert opinion and this can also be independently veriﬁed
by review of the published document. Recommendations
not exceeding strength of evidence, is crucial for limiting
bias, as well as preserving clinician autonomy and ﬂexi-
bility of clinical judgment where restriction would be
unjustiﬁed. Preventing unjustiﬁed restriction of clinical
practice as well as a representative and expert composition
of the multidisciplinary writing groups are the two most
important features for maximizing the chance of guideline
acceptance and utilization by clinicians. The evidence-
linked multidisciplinary guideline published in this special
issue is a historic milestone, as it represents the ﬁrst effort
using this formal methodology for managing metastatic
brain tumors produced by a representative multidisciplin-
ary writing panel of experts.
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Over the last 16 years, the AANS and CNS and their
associated joint subspecialty sections have participated in,
completed, and approved eight different EBM clinical
practice guidelines. A feasibility study by the CNS com-
pleted in 2005 revealed that each effort took on average
3 years to complete (range 2–5 years) relying solely on
volunteer efforts of the physician writing group members.
Given that the average EBM clinical practice guideline
validity shelf life is only 5–7 years before the evidence
review it is too out of date to be relied upon, it was clear
that the time to completion really cuts into the useful shelf
life of the resultant guideline. Each effort also involved
production costs ranging between $20 and $100,000 inde-
pendent of potential publication costs if the journal
required publication as a paid supplement.
It was clear that a more professional solution was nee-
ded, particularly to expedite the ﬁrst phase of guidelines
construction involving the systematic literature review,
evidence sifting and screening, formation of ﬁnal evidence
tables and initial grading of evidence strength based on
study methodology. Rather than hire their own epidemi-
ologists, research librarians and assistant infrastructure, as
well as develop the in-house hardware and software needed
for this portion, the AANS and CNS decided to try a pilot
project contracting with an established EPC.
AHRQ EPCs and the process for this project
The Agency for Health Care Policy and Research (AH-
CPR) was established as a Public Health Service agency
within the Department of Health and Human Services
(HHS) in December 1989 under Public Law 101-239 [14].
It was tasked with promoting quality of healthcare,
reducing its cost, improving patient safety, decreasing
medical errors, and broadening access to essential services
by supporting outcomes studies, and implementing their
ﬁndings through the dissemination of clinical guidelines. In
1999 the name of the agency was changed to the Agency
for Healthcare Research and Quality (AHRQ) [15].
The AHRQ is responsible, among other things, for
compilation and publication of the national healthcare
report card and helping to maintain the national guidelines
clearinghouse (www.ngc.gov). However, approximately
75% of its annual budget goes towards providing 5-year
grants to fund EPCs in North America, of which there are
now 14 (Table 1). The EPCs are charged with reviewing all
relevant scientiﬁc literature on clinical, behavioral, and
organization and ﬁnancing topics to produce evidence
reports and technology assessments. These reports are used
for informing and developing coverage decisions, quality
measures, educational materials and tools, guidelines and
research agendas. They also are tasked with doing research
on methodology of systematic reviews [16].
The AANS and CNS are not the ﬁrst medical profes-
sional society organizations to consider contracting with an
EPC. The ﬁrst neurosurgery afﬁliated organization to do so
was the BTF, which has contracted with the Oregon EPC at
the Oregon Health Sciences University to work with them
on regularly helping with revisions and updates of the
severe head injury guidelines. Another non-neurosurgical
example is the National Kidney Foundation which has
developed a retainer contract with Tufts—New England
Medical Center EPC to assist with their Outcomes Quality
Initiatives guidelines effort.
The AANS and CNS sent a request for proposal to 13
AHRQ-EPCs in October 2006. Four EPCs initially
expressed interest and three ultimately submitted proposals
for review. The McMaster University EPC won the con-
tract after careful study by the AANS/CNS Joint Guide-
lines Committee through the Spring of 2007. The contract
was negotiated and ﬁnalized in the Fall of 2007. The
project began in February 2008 and was completed in May
2009. The AANS/CNS Joint Guidelines Committee review
and response to review were completed by August 2009,
and AANS and CNS approval conferred later that month.
Advantages of EPCs
There are distinct advantages for professional societies
working with established EPCs to create EBM clinical
practice guidelines. Many of the AHRQ-funded EPC’s
have extensive experience in all areas of EBM and many
are actively involved in research efforts to advance EBM to
the next level. They are professionals. This is what they do.
Table 1 List of current AHRQ-funded evidence-based practice
centers
BC/BS Association, Technology Evaluation Center EPC
Duke University EPC
ECRI Institute EPC
Johns Hopkins University EPC
McMaster University EPC
Minnesota EPC
Oregon EPC
RTI International—University of NC EPC
Southern California EPC
Tufts—NE Medical Center EPC
University of Alberta EPC
University of Connecticut EPC
University of Ottawa EPC
Vanderbilt University EPC
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for its seminal contributions to the EBM literature. Alumni
and/or current faculty at McMasters include such EBM
luminaries as David Sackett and Gordon Guyatt, among
many others. EPC’s are brimming with experienced epi-
demiologists at both the PhD and masters degree level, as
well as graduate students looking to make their mark
working on clinically relevant epidemiology projects. They
have the research staff and hardware and software infra-
structure in place to support even the largest conceived
projects. Overall, they are in a better position to provide the
highest quality literature search, evidence sifting, and ini-
tial evidence table organization in the shortest possible
time, than just about any professional medical society.
On the other hand, the medical professional societies
contain the clinical subject matter experts that are neces-
sary and critical for ﬁnal review and assessment of the
evidence in the evidence tables, creation of the subsequent
clinical recommendations, and adjudication of the strength
of recommendations created. Guidelines construction
methodology and multidisciplinary panel composition are
equally important in determining the overall quality and
validity of the guideline produced. However, multidisci-
plinary panel composition is probably even more important
than guidelines construction methodology in inﬂuencing
subsequent guideline buy-in, acceptance, and implemen-
tation by clinicians for clinical care. An EBM clinical
practice guideline unilaterally produced by EPC epidemi-
ologists is far less likely to be adopted, regardless of its
degree of methodological purity.
Areas that could be improved
The biggest drawback to continuing to follow this paradigm
is the cost involved. This pilot project for EBM clinical
practice guidelines cost the AANS, CNS, and the Joint
TumorSection*$250,000toproduce.Giventhenumberof
areas of neurosurgical practice that are crying out for
guidelinesdevelopmentcoupledwiththeneedtorevisethese
guidelines approximately every 5 years, it becomes clear
that the whole budget of these organizations could very
rapidly become consumed with the need to produce and
revise EBM clinical practice guidelines. Regardless of the
altruisticintentofthemedicalorganizationorthestrengthof
thedesiretoserveourpatientsandmembers,thisdutywould
soon become economically unsustainable.
Given that EBM clinical practice guidelines have the
strong potential to beneﬁt hospitals, private insurance
companies, government third party payers, the US gov-
ernment budget, patients, and society as a whole, a better
means of addressing guidelines development cost would
seem to be in order. The AHRQ is a division of the US
Government under the Department of HHS. It is currently
spending over $200,000,000 per year funding EPC’s. It
would seem that this funding and granting arrangement
could be revised to better align incentives to promote EPC
and professional medical society collaboration and part-
nership, promote joint EBM clinical practice guideline
development, and control costs to nonproﬁt professional
medical societies who provide the expert panel writing
group expertise. Speciﬁc suggestions include:
(A) Making EPC collaboration with professional medical
societies for the purpose of EBM clinical practice
guideline development a condition for AHRQ grant
funding and/or part of grant evaluation for success or
continuance
(B) Providing matching funds for professional medical
societies to contract with AHRQ-funded EPCs for the
purpose of EBM clinical practice guideline
development
(C) Create a condition for AHRQ EPC funding that
would exempt professional medical societies form
paying indirect costs when contracting with EPCs for
the purpose of EBM clinical practice guideline
development (indirect costs constituted 40% of the
$250,000 spent on the current EBM clinical practice
guideline effort).
Conclusion
In the absence of better cost sharing planning and regula-
tions for EBM clinical practice guideline development, the
synergistic advantages of EPC—professional medical
society partnerships may not be cost effective or sustain-
able. Alternatives include individual professional medical
societies hiring a minimum core of their own epidemiolo-
gists, researchers, and other support personnel and main-
taining their own hardware and software infrastructure as
ﬁxed annual costs, to work with their members on these
projects. This would be better than the worst case scenario
of abandoning EBM clinical practice guideline efforts all-
together, but would suffer from failing to leverage the
existing professional expertise and infrastructure power of
our 14 tax payer-funded EPCs.
The brain metastasis EBM clinical practice guideline
presented in this special edition of the Journal of Neuro-
Oncology is a powerful and exciting new addition for
optimizing the quality of care for our patients with meta-
static brain tumors. As a new AANS, CNS and Joint Tumor
Section pilot project for exploring the feasibility and utility
of contracting with an AHRQ-funded EPC for producing
the highest quality EBM clinical practice guidelines in the
shortest possible period of time, it has been a resounding
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to all areas of medicine and many other professional
medical societies. paradigm Whether or not it becomes
economically sustainable over time depends in large part
on funding re-engineering and planning efforts outside
professional medical society control, at the health policy
and governmental level within such departments as the
Department of HHS.
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